ASSESSMENT OF PROINFLAMMATORY MARKERS IN TYPE 2 DIABETIC PATIENTS POSTCOVID-19 VACCINATION

Background: COVID-19 Caused by Severe Acute Respiratory Syndrome COVID-2 (SARS-CoV-2). Type 2Diabetes Mellitus(T2DM) is a metabolic disorder associated with poor clinical outcomes in COVID-19 patients. This study aims to compare proinflammatory markers, such as TNF-α and IL-6, between T2DM patients and healthy controls after COVID-19 vaccination. Materials and Methods: This study was conducted at Teerthanker Mahaveer University, College of Paramedical Sciences, Moradabad. A total of 130 subjects were included, divided equally into two groups: 65 T2DM patients and 65 healthy controls. Blood samples were collected under aseptic conditions and analyzed in the laboratory. P-value less than 0.05 considered significance. Results: The study included 43 males (66.15%) and 22 females (33.84%) in the Healthy control group, and 46 males (70.76%) and 19 females (29.23%) in the T2DM group. The mean TNF-α levels were significantly higher in the T2DM group (32.16 ± 5.11 pg/ml) compared to the control group (5.58 ± 1.02 pg/ml), with a Z-test value of -41.04 (P < 0.05). Similarly, the mean IL-6 levels were higher in the T2DM group (19.70 ± 2.26 pg/ml) compared to the control group (5.11 ± 1.02 pg/ml), with a Z-test value of -48.00 (P < 0.05). Conclusion: T2DM patients exhibited significantly elevated levels of proinflammatory markers TNF-α and IL-6 compared to healthy controls after COVID-19 vaccination.